- Home
- SPT vs CRMD Comparison
SPT vs CRMD Comparison
Compare SPT & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- CRMD
- Stock Information
- Founded
- SPT 2010
- CRMD 2006
- Country
- SPT United States
- CRMD United States
- Employees
- SPT N/A
- CRMD N/A
- Industry
- SPT Computer Software: Prepackaged Software
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- CRMD Health Care
- Exchange
- SPT Nasdaq
- CRMD Nasdaq
- Market Cap
- SPT 799.3M
- CRMD 925.6M
- IPO Year
- SPT 2019
- CRMD 2010
- Fundamental
- Price
- SPT $13.65
- CRMD $12.94
- Analyst Decision
- SPT Buy
- CRMD Strong Buy
- Analyst Count
- SPT 10
- CRMD 8
- Target Price
- SPT $27.70
- CRMD $17.57
- AVG Volume (30 Days)
- SPT 1.0M
- CRMD 4.6M
- Earning Date
- SPT 11-06-2025
- CRMD 10-29-2025
- Dividend Yield
- SPT N/A
- CRMD N/A
- EPS Growth
- SPT N/A
- CRMD N/A
- EPS
- SPT N/A
- CRMD 0.79
- Revenue
- SPT $430,795,000.00
- CRMD $121,484,498.00
- Revenue This Year
- SPT $13.01
- CRMD $404.81
- Revenue Next Year
- SPT $11.79
- CRMD $56.11
- P/E Ratio
- SPT N/A
- CRMD $16.35
- Revenue Growth
- SPT 14.79
- CRMD 14970.29
- 52 Week Low
- SPT $13.33
- CRMD $5.60
- 52 Week High
- SPT $36.30
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- SPT 35.99
- CRMD 49.60
- Support Level
- SPT $14.57
- CRMD $12.73
- Resistance Level
- SPT $15.56
- CRMD $13.83
- Average True Range (ATR)
- SPT 0.64
- CRMD 0.75
- MACD
- SPT -0.00
- CRMD -0.16
- Stochastic Oscillator
- SPT 4.03
- CRMD 40.24
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.